BSW Wealth Partners’s Viridian Therapeutics VRDN Stock Holding History

BSW Wealth Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,482	Closed	-$67K	–	108
2018 Q4	$67K	Sell	1,482 -10,849	-88%	-$627K	0.03%	92
2018 Q3	$9.29M	Buy	12,331 +10,849	+732%	+$1.02M	3.54%	6
2018 Q2	$143K	Buy	+1,482	New	+$157K	0.06%	88
2018 Q1	–	Sell	-1,482	Closed	-$232K	–	96
2017 Q4	$232K	Hold	1,482	–	–	0.1%	74
2017 Q3	$203K	Buy	+1,482	New	+$249K	0.09%	82

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BSW Wealth Partners's VRDN Position: Q1 2019 in Review

BSW Wealth Partners sold out of Viridian Therapeutics (VRDN) in Q1 2019, closing a stake of 1,482 shares — an estimated $67K sold.

BSW Wealth Partners first reported a position in VRDN in Q3 2017 and held it in 5 quarters. The position peaked at $9.29M in Q3 2018. 51 funds tracked by Wall St. Rank hold VRDN as of Q1 2019.

BSW Wealth Partners reported no remaining Viridian Therapeutics position as of Q1 2019 after selling out during the quarter.
BSW Wealth Partners sold 1,482 Viridian Therapeutics shares in Q1 2019, an estimated $67K.
BSW Wealth Partners first reported a position in Viridian Therapeutics in Q3 2017 and held it in 5 quarters.
BSW Wealth Partners's Viridian Therapeutics position peaked at $9.29M in Q3 2018.
51 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2019.

Based on BSW Wealth Partners's 13F filing for Q1 2019, filed 14 May 2019.